Drugs in ATC Class C05AD

Up to Top Level ATC Classes

Up to C - Cardiovascular system

Up to C05 - VASOPROTECTIVES

Up to C05A - AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE

Drugs in ATC Class: C05AD - Local anesthetics

Tradename	Generic Name
DECADRON W/ XYLOCAINE	dexamethasone sodium phosphate; lidocaine hydrochloride
DUOCAINE	bupivacaine hydrochloride; lidocaine hydrochloride
EMBOLEX	dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride
LANABIOTIC	bacitracin zinc; lidocaine; neomycin sulfate; polymyxin b sulfate
LIGNOSPAN FORTE	epinephrine bitartrate; lidocaine hydrochloride
LIGNOSPAN STANDARD	epinephrine bitartrate; lidocaine hydrochloride
ROCEPHIN KIT	ceftriaxone sodium; lidocaine

C05AD Market Analysis and Financial Projection

The ATC class C05AD (Local Anesthetics) includes topical agents like lidocaine, tetracaine, benzocaine, and cinchocaine, primarily used to manage hemorrhoids, anal fissures, and pruritus. Market dynamics and patent activity in this segment reflect both steady demand and evolving innovations.

---

Market Dynamics

Market Size and Growth

• Projected Growth: The global local anesthesia drugs market is expected to reach USD 5.14–6.22 billion by 2030, growing at a CAGR of 3.4–3.6% (2024–2030) [3][7][16].
• Hemorrhoid-Specific Market: Hemorrhoid treatments, where C05AD drugs play a key role, were valued at USD 1.03 billion in 2023 and are projected to hit USD 1.74 billion by 2032 [10].

Key Drivers

1. Surgical Volume: Rising demand for cosmetic, dental, and minimally invasive surgeries (e.g., over 2.3 million U.S. cosmetic procedures in 2023) [3][14].
2. OTC Accessibility: Local anesthetics like lidocaine ointments dominate OTC hemorrhoid treatments, accounting for the second-largest market share after corticosteroids [10].
3. Technological Advances:
   • Ultrasound-guided administration and robotic delivery systems [3].
   • Sustained-release formulations (e.g., bupivacaine) to prolong efficacy [13].

Competitive Landscape

Drug	Market Position	Key Use Cases
Lidocaine	Market leader (25% share) [15]	Hemorrhoids, dental procedures
Tetracaine	Growing adoption in combinations [8]	Surgical/local analgesia
Benzocaine	Widely used in OTC products [9]	Topical pain relief
Cinchocaine	Featured in Botswana’s health plans [1][5]	Hemorrhoid suppositories

---

Patent Landscape

Historical Trends

• First Patent: US628489A (1897) for a non-volatile local anesthetic [4].
• 1960–1990: Average of 50 patents/year filed [4].
• Recent Activity: Over 8,000 patent families analyzed, focusing on formulation improvements and combination therapies [4].

Recent Innovations

1. Combination Therapies:
   • Pharmavax AS (2024): Patented combinations of lidocaine/tetracaine for prolonged pain relief [8].
   • PP-110 Gel: Combines pramoxine and phenylephrine in a film-forming delivery system [13].
2. Delivery Systems:
   • Patents for lidocaine/tetracaine patches (e.g., USPTO 10350180 expiring 2031) [11].

Regulatory and Economic Factors

• Cost Pressures: Untreated hemorrhoids incur high hospitalization costs, driving demand for affordable OTC solutions [10].
• Regulatory Hurdles: FDA/EMA approvals for new formulations remain stringent, slowing market entry [10].

---

Emerging Opportunities

• Telemedicine: Increased adoption of digital platforms for sensitive conditions like hemorrhoids [10].
• Novel Targets: Research into butyl-amino-benzoate derivatives and charged molecules for enhanced efficacy [3].

---

"The integration of ultrasound-guided regional anesthesia techniques has revolutionized the precision of local anesthetic administration." [3]

The C05AD segment remains robust, fueled by surgical demand and innovation. Patent activity highlights a shift toward combination therapies and advanced delivery systems, while regulatory challenges persist.

References

1. https://www.metropolitan.co.bw/common_up/metropolitan-health/01-08-2017_BOTSOGO%20HEALTH%20PLAN%20MEDICINE%20PRICE%20LIST%202017.xlsx
2. https://go.drugbank.com/drugs/DB09085
3. https://www.mordorintelligence.com/industry-reports/local-anesthesia-drugs-market
4. https://www.markipservices.com/patent-landscapes/ex-1-p-l-on-anesthesia
5. https://www.metropolitan.co.bw/common_up/metropolitan-health/31-07-2017_Botsogo%20Health%20Plan%20Medicine%20Price%20List%202017.xlsx
6. https://prediction.charite.de/subpages/tree.php
7. https://www.researchandmarkets.com/reports/5998671/local-anesthesia-drugs-market-size-share-and
8. https://go.gale.com/ps/i.do?id=GALE%7CA809526312&sid=sitemap&v=2.1&it=r&p=HRCA&sw=w
9. https://go.drugbank.com/drugs/DB01086
10. https://www.fortunebusinessinsights.com/hemorrhoid-treatment-market-110985
11. https://www.pharmakb.com/drug-report/tetracaine
12. https://www.atccode.com/C05AD
13. https://epublications.vu.lt/object/elaba:192964802/192964802.pdf
14. https://www.novaoneadvisor.com/report/local-anesthesia-drugs-market
15. https://www.sphericalinsights.com/reports/local-anesthesia-drugs-market
16. https://www.globenewswire.com/news-release/2024/11/11/2978108/28124/en/Local-Anesthesia-Drugs-Market-Size-Share-Trends-Analysis-Report-2024-2030-Regional-Insights-for-Bupivacaine-Ropivacaine-Lidocaine-Chloroprocaine-Prilocaine-Benzocaine-and-Other-Loc.html